Immunotherapy: Recurrent and/or metastatic head and neck cancer portends a poor prognosis with traditional treatments, but current immunotherapy with immune checkpoint inhibitors has the potential to improve these clinical outcomes. This review focuses on the major breakthroughs that have led to the current understanding of immunotherapy in head and neck cancer as well as the future direction of the field. Ultimately, this understanding will guide clinicians on the selection of patients with head and neck cancer and practical considerations before starting immunotherapy.
http://ift.tt/2uzxiwD
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Background HIV progression is characterized by immune activation and microbial translocation from the gut. Short-chain fatty ac...
-
Publication date: Available online 8 April 2017 Source: European Journal of Vascular and Endovascular Surgery Author(s): J.P. Archie ...
-
Epidemiology and predictive factors of fungal malignant otitis externa Rim Bechraoui, Mohamed Dhaha, Houda Chahed, Amal Ksentini, Rim Zainin...
-
Testicular tumours are the most common tumours in young men. Germ cell tumours (GCTs) account for 95% of all testicular cancers, and the non...
-
Abstract The potential for cardiac implantable electronic device leads to interfere with tricuspid valve (TV) function has gained increasin...
-
The original version of this article unfortunately contained a mistake in the author name. The co-author name should be Hiroyuki Matsuura in...
-
Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight. Int J Pharm. 2016 Aug 16;...
-
Publication date: Available online 28 February 2017 Source: Neuroscience Research Author(s): Soshi Tanabe, Ken-ichi Inoue, Hitomi Tsuge, ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου